ArticleInfectious disorders drug targets2025
Antibacterial Effect of Co-Loaded Curcumin and Rutin in Mesoporous Silica Nanoparticles Compared to their Loading Alone.
Article in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microfluidic-assembled curcumin ionizable lipid nanoparticles enhance aqueous delivery and antibiofilm activity againstInternational journal of pharmaceutics: X · 2026Article
- Synthesis and characterization of curcumin-loaded cellulose nanoparticles targeting bacterial quorum sensing and biofilms in foodborne bacteria.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsThe present study aimed to assess the antibacterial effect of co-loaded rutin and curcumin in mesoporous silica nanoparticles (Cur-Rut-MSNs).
backgroundRutin is a nontoxic phytochemical that is present expansively in vegetables and fruits. Curcumin is an active ingredient of Curcuma longa. Curcumin and rutin have a variety of therapeutic effects, essentially antimicrobial, anti-inflammatory, and antioxidant actions.
objectiveLow aqueous solubility and poor bioavailability of rutin and curcumin limit their application in therapeutic goals. One of the advantageous routes to improve their bioavailability and solubility is nanoformulation. Co-delivery of therapeutic agents has been reported to have better therapeutic effects than monotherapy.
methodsThe present study has evaluated the antibacterial properties of Cur-Rut-MSNs. The Minimum Inhibitory Concentration (MIC) of Cur-Rut-MSNs has been assessed against different bacteria.
resultsCur-Rut-MSNs exerted significantly higher antibacterial effect than curcumin-loaded MSNs (Cur-MSNs) and rutin-loaded MSNs (Rut-MSNs) against Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, and Enterococcus faecalis (p<0.05).
conclusionThe antibacterial effect was enhanced by the co-loading of rutin and curcumin in MSNs. According to the findings of this study, Cur-Rut-MSNs exhibit an antibacterial effect and can be a favorable nanoformulation against planktonic bacteria.
Indexed as
Identifiers
39313891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.